PERMALINK Trademark
PERMALINK is a USPTO trademark filed by IKSUDA THERAPEUTICS LIMITED. Status: Cancelled.
Trademark Facts
| Mark | PERMALINK |
|---|---|
| Serial Number | 79160241 |
| Registration Number | 4899840 |
| Status | Cancelled |
| Filing Date | 2014-12-08 |
| Registration Date | 2016-02-16 |
| Mark Type | Word |
| Nice Classes | 001 (Chemicals), 016 (Paper Goods), 042 (Software & IT) |
| Owner | IKSUDA THERAPEUTICS LIMITED |
| Attorney of Record | Christina M. Licursi |
| Prosecution Events | 44 |
| Latest Event | DENA on 2025-06-27 |
Goods & Services
Paper; cardboard; printed matter, namely, paper signs, books, manuals, business cards, newsletters, informational cards, posters, brochures, letters, data packages, certificates in the field of biotherapeutics; bookbinding material; photographs; stationery; Printed instructional, educational, and teaching materials in the field of medicine; publications, namely, books, hand-outs, workbooks, posters, research articles in the fields of science, medicine and biotherapeutics; publications for the medical profession, namely, magazines, newsletters, research articles in the field of medicine; Chemicals used in industry and science; chemical products for use in industry and science, namely, vinyl pyridine-based linkers and vinyl pyridine derivatives; reagents for use in scientific apparatus for chemical or biological analysis; reagents for medical research; in-vivo diagnostic reagents; chemical preparations for scientific and industrial processes, namely, vinyl pyridine-based linkers and vinyl pyridine derivatives; enzymes for scientific and industrial purposes; biological cell cultures for use in scientific research; Scientific and technological services, namely, scientific research, design, analysis and testing in the field of biotherapeutics for treating cancer; industrial analysis and research services, namely, synthetic chemistry, bioconjugation, and scientific analysis of antibody-drug conjugates and biotherapeutics; biological research; biotechnology testing services, namely, synthetic chemistry, recombinant protein production, bioconjugation, testing, analysis, and evaluation of antibody-drug conjugates and biotherapeutics to assure compliance with industry standards; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; conducting clinical trials for others; design of clinical trials for others in the field of vaccines, biotherapeutics and antibody-drug conjugates; scientific research for medical purposes; scientific research for medical purposes in the area of cancerous diseases; information, advisory and consultancy services relating to the aforesaid